ImmuPharma plc
ImmuPharma plc (IMMPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
immpf · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ImmuPharma plcYou IMMPF | $28M | N/A | — | -$0.01 |
 Alpha Cognition Inc. ACOGF | $36M | N/A | — | -$0.15 |
 Chill Brands Group PLC CHBRF | $24M | N/A | — | -$0.01 |
 Small Pharma Inc. DMTTF | $38M | N/A | — | -$0.07 |
 OKYO Pharma Limited EMMLF | $23M | N/A | — | — |
 Generation Hemp, Inc. GENH | $25M | N/A | — | -$0.06 |
 IBEX Technologies Inc. IBXNF | $25M | 6.80x | — | $0.16 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ImmuPharma plc (IMMPF) measures how much investors pay for each dollar of the company's trailing earnings. IMMPF's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$0.01.
Frequently asked questions
IMMPF pe ratio · 6 questionsIMMPF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.09 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via IMMPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ImmuPharma plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08